Evrenzo self attestation

Are you a Healthcare Professional?

This site is intended only for Healthcare Professionals, particularly those who are experienced in the management of anaemia associated with chronic kidney disease.

I AM NOT A HEALTHCARE PROFESSIONAL
evrenzo leavingsoon

You are leaving the website

You are now leaving an Astellas Pharma Ltd. website.
Astellas bears no responsibility for the content of any 3rd party material
nor how it might be used. Click OK to proceed.

Dialysis-dependent

  • EVRENZO was as effective as ESA in patients new to dialysis1

    Dialysis dependent table

    Patients recently started on dialysis and treated with EVRENZO achieved and maintained target Hb levels comparable with those treated with ESA1

    Dialysis Dependent 1

    DD, dialysis-dependent; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IDD, incident dialysis-dependent; NDD, non-dialysis-dependent.

    Reference

    • EVRENZO SmPC 09.2024 sect. 5.1

  • EVRENZO reduces dependence on IV iron in patients new to dialysis1

    Dialysis dependent table

    Patients recently started on dialysis and treated with EVRENZO used less monthly IV iron than those treated with ESA1

    Dialysis Dependent 2

    Reference

    • EVRENZO SmPC 09.2024 sect. 5.1
    • Barrat J, Sulowicz W, Schömig M et al. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies. Adv Ther. 2021;38(10):5345-5360

  • EVRENZO summary in DD

    Dialysis Dependent 3

    In dialysis-dependent CKD, EVRENZO can help your patients meet and maintain their Hb targets1

    • EVRENZO demonstrated non-inferiority in Hb correction and maintenance compared to ESA1

    • EVRENZO treatment resulted in reduced use of IV iron supplementation compared with treatment with ESA in patients just started dialysis1

    • Patients currently treated with an ESA can be converted to EVRENZO, however, conversion of dialysis patients otherwise stable on ESA treatment is only to be considered when there is a valid clinical reason2

    CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous.

    Reference

    • EVRENZO SmPC 09.2024 sect. 5.1
    • EVRENZO SmPC 09.2024 sect. 4.2